Enables Layout without Multi-Layer PCB for Cost Saving

TOKYO - Saturday, June 15th 2013 [ME NewsWire]

(BUSINESS WIRE)-- Toshiba Corporation (TOKYO:6502) today announced that it has expanded its package line-up of interface-converter bridge LSIs for high resolution LCD display that are used in tablet PC, Ultrabooks™ and other applications. Mass production of "TC358778XBG" is scheduled to start in June, followed by "TC358777XBG" in July.

The ball pitch of the original product is 0.4mm, and fine pitch assembly equipment is required for production. Expanding the ball pitch from 0.4mm to 0.65mm achieves assembly with no need for such equipment. Toshiba has also optimized the pin assignment for layout without high cost PCB with more than 4 layers.

Those new package products reduce the set makers' cost of assembly and materials.
 

Key Features

1.
          

Ball pitch expanded from 0.4mm to 0.65mm< ... Read more »

SAN DIEGO - Saturday, June 15th 2013 [BUSINESS WIRE/ ME NewsWire]

-- Pathway Genomics, a genetic testing laboratory on the forefront of bringing physicians a broad genetic testing portfolio covering a wide range of diseases, announces the pending launch of its inherited cancer panel with BRCA1 and BRCA2.

Pathway Genomics’ Hereditary Cancer DNA InsightSM test utilizes next-generation sequencing (NGS) technology and will analyze genes related to a selection of hereditary cancers including breast, ovarian, colorectal and others. The company notes that it intends to introduce all their cancer panels in August 2013.

"I am delighted to see laboratories like Pathway offering genetic tests for inherited cancers,” said Linda Wasserman, M.D., Ph.D., former Director of the Clinical Cancer Genetics Care Unit at Moores UCSD Cancer Center. "Next-generation sequencing is a critical step in making actionable genetic information more accessible to the physician, ultimately benefitt ... Read more »

INGELHEIM, Germany - Thursday, June 13th 2013 [ME NewsWire]

For media outside USA, UK and Canada only

    In the Phase IIb SOUND-C3 study, all but one patient achieved viral cure with faldaprevir+ and deleobuvir+ (BI 207127) plus ribavirin, without a need for interferon
    The study included challenging-to-cure patients with advanced liver disease, all of whom achieved viral cure

(BUSINESS WIRE)-- New data from Boehringer Ingelheim’s interferon-free SOUND-C3 study were presented during the APASL Liver Week in Singapore. The Phase IIb study investigated the efficacy and safety of faldaprevir+ and deleobuvir+ (BI 207127) plus ribavirin in treatment-naïve patients with genotype-1b (GT-1b) hepatitis C virus (HCV),1 one of the most common types of HCV globally.2

Results showed that 95% of genotype-1b (GT-1b) infected patients (19/20) who received BI’s interferon-free combination therapy achieved viral cure after 16 weeks of treat ... Read more »